Other languages Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
102.8 ^USD	+0.41%		-2.05%	+11.46%

May. 23	Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer	MT
May. 23	Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting	May. 23
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	May. 06
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	May. 02
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	May. 02
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	Mar. 22
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	Mar. 01
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	Feb. 23
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 23
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	Feb. 22
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	Feb. 15
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	Feb. 15
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 15
Blueprint Medicines Insider Sold Shares Worth $395,350, According to a Recent SEC Filing	Dec. 13
Blueprint Medicines Receives European Approval for Ayvakyt in Indolent Systemic Mastocytosis	Dec. 12
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis	Dec. 12
Blueprint Medicines Insider Sold Shares Worth $375,000, According to a Recent SEC Filing	Dec. 11
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting	Dec. 09
Blueprint Medicines Insider Sold Shares Worth $352,750, According to a Recent SEC Filing	Dec. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Other languages

Filters